Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2005

View Archived Issues

Dong-A PharmTech files IND for new PDE5 inhibitor for erectile dysfunction

Medicis and Inamed to merge

Protein Design Labs completes acquisition of ESP Pharma

Procalcitonin (PCT) as an effective biomarker for the diagnosis and prognosis of severe sepsis

Vion initiates phase III study of Cloretazine in relapsed AML

Phase II study evaluates MN-001 in asthma

Dosing under way in phase I study of CR-665 for postoperative pain

Enrollment under way in phase II study of AVR-118 in advanced cancer patients

Japanese licensing agreement for Posurdex

Citrus flavonoid F-1 protects rats from beta--amyloid-induced learning impairment

MM-101 produces favorable effects in preclinical models of diabetic hypoalgesia and neuropathic pain

Lilly issues Xigris warning

InterMune works towards phase III program for pirfenidone in IPF

SGS-518 safe, well tolerated in phase I study

TolerRx completes Series D financing

Yamanouchi confirms termination of Cogane licensing agreement

Treatment for heart tissue degeneration disclosed in patent

Bayer claims LDL-PLA2 inhibitors

New matrix metalloproteinase inhibitors for respiratory disorders emerge from Pfizer research

Researchers at Janssen describe agents for gastrointestinal disorders

Promising effects reported for Proxinium in head and neck cancer

Good safety profile found for single doses of AEOL-10150 in patients with Lou Gehrig's disease

Long-term benefits of intramyocardial VEGF-2 in patients with intractable angina

GH therapy improves insulin sensitivity in postmenopausal women with abdominal obesity

Nonapprovable letter for Lexapro in social anxiety disorder

NDA filed for Nuvigil

Xeloda approved in E.U. as adjuvant therapy for colon cancer

Nycomed seeks European approval for Preotact

Perindopril cardioprotective in children with Duchenne muscular dystrophy